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A role for endothelial nitric oxide synthase
in intestinal stem cell proliferation and
mesenchymal colorectal cancer
Jon Peñarando1, Laura M. López-Sánchez1,2, Rafael Mena1, Silvia Guil-Luna1, Francisco Conde1,2,
Vanessa Hernández1, Marta Toledano1,2, Victoria Gudiño6, Michela Raponi6, Caroline Billard6, Carlos Villar3,
César Díaz4, José Gómez-Barbadillo4, Juan De la Haba-Rodríguez1,2,5, Kevin Myant6, Enrique Aranda1,2,5
and Antonio Rodríguez-Ariza1,2,5*
Abstract
Background: Nitric oxide (NO) has been highlighted as an important agent in cancer-related events. Although the
inducible nitric oxide synthase (iNOS) isoform has received most attention, recent studies in the literature indicate that the
endothelial isoenzyme (eNOS) can also modulate different tumor processes including resistance, angiogenesis, invasion,
and metastasis. However, the role of eNOS in cancer stem cell (CSC) biology and mesenchymal tumors is unknown.
Results: Here, we show that eNOS was significantly upregulated in VilCreERT2Apcfl/+ and VilCreERT2Apcfl/fl mouse intestinal
tissue, with intense immunostaining in hyperproliferative crypts. Similarly, the more invasive VilCreERT2Apcfl/+ Ptenfl/+ mouse
model showed an overexpression of eNOS in intestinal tumors whereas this isoform was not expressed in normal tissue.
However, none of the three models showed iNOS expression. Notably, when 40 human colorectal tumors were classified
into different clinically relevant molecular subtypes, high eNOS expression was found in the poor relapse-free and overall
survival mesenchymal subtype, whereas iNOS was absent. Furthermore, Apcfl/fl organoids overexpressed eNOS compared
with wild-type organoids and NO depletion with the scavenger carboxy-PTIO (c-PTIO) decreased the proliferation and the
expression of stem-cell markers, such as Lgr5, Troy, Vav3, and Slc14a1, in these intestinal organoids. Moreover, specific NO
depletion also decreased the expression of CSC-related proteins in human colorectal cancer cells such as β-catenin and
Bmi1, impairing the CSC phenotype. To rule out the contribution of iNOS in this effect, we established an iNOS-
knockdown colorectal cancer cell line. NO-depleted cells showed a decreased capacity to form tumors and c-PTIO
treatment in vivo showed an antitumoral effect in a xenograft mouse model.
Conclusion: Our data support that eNOS upregulation occurs after Apc loss, emerging as an unexpected potential new
target in poor-prognosis mesenchymal colorectal tumors, where NO scavenging could represent an interesting
therapeutic alternative to targeting the CSC subpopulation.
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Background
Advances in understanding the molecular pathways in
colorectal cancer (CRC) have resulted in the development
of novel targeted therapeutics [1]. However, CRC remains
the third most frequent cancer and the fourth leading cause
of cancer deaths worldwide [2]. The cancer stem cell (CSC)
model provides an attractive explanation to these mortality
data and therapy failure [3]. In the CSC model, a small sub-
population of tumor cells possesses unlimited proliferative
potential and chemoresistance, ultimately resulting in a
tumor spreading and metastasis [4]. Thus, this cellular sub-
set with tumor-initiating properties has the capacity to
evade conventional therapies, which contributes to the ad-
verse survival rates, so new specific targets must be found
[5]. Moreover, the heterogeneity of CRC hinders the selec-
tion of patients who will respond better to therapy and the
detection of new targeted agents [6]. To solve this problem,
several gene-expression-based CRC classifications have
been reported, dividing the disease into different clinically
relevant CRC subtypes [6–10]. Recently, the International
CRC Subtyping Consortium analyzed different CRC data
sets and have described four robust consensus molecular
subtypes (CMSs) associated with clinical variables [11]:
CMS1 (microsatellite instability), CMS2 (canonical), CMS3
(metabolic), and CMS4 (mesenchymal). Interestingly, al-
though these classifications differed in the number of
tumor subtypes, they all agree in the identification of a
stem-like mesenchymal subtype, which is associated with
poor patient outcome in CRC [11], so new specific targets
must be discovered to improve current treatments.
Nitric oxide (NO) has been highlighted as an important
agent in different physiopathological conditions, including
colon cancer [12]. It has been shown that NO has a dual
role in tumoral processes, being cytotoxic or cytostatic at
high levels whereas low levels can have the opposite effect
and promote tumor growth [13]. This molecule is synthe-
sized by three different NO synthase (NOS) isoforms
using L-arginine and molecular oxygen as substrates:
neuronal NOS (nNOS), inducible NOS (iNOS), and endo-
thelial NOS (eNOS) [14]. The inducible isoform has been
the center of attention in the study of its role in tumori-
genesis [15]. However, there is a huge controversy about
the expression and role of iNOS in human colon carcino-
genesis. Whereas some authors seem to detect iNOS ex-
pression in 60% of human colon adenomas [16], other
studies reported that levels of this isoenzyme were low or
absent at all stages of colon cancer [17, 18]. Moreover,
conflicting results for the role of iNOS in colon tumori-
genesis have been found by independent groups using the
same Min mouse model [19, 20]. On the other hand, re-
cent works in the literature indicate that eNOS may be
implicated in different tumor processes, such as resistance
to hormonal therapy [21], angiogenesis, invasion, and me-
tastasis [22]. Furthermore, high levels of eNOS have been
correlated with an angiogenic phenotype and predict poor
prognosis in human gastric cancer [23]. Despite the rela-
tion between tumor-expressed eNOS and tumor mainten-
ance [24], there are no data about the role of this protein
in the stem-cell-like population responsible for the initi-
ation and maintenance of tumor growth.
In the present study, by employing three different
independent mice models, we show that eNOS up-
regulation is an early event in CRC after Apc loss
and it is also upregulated in the human mesenchy-
mal CRC subtype. Moreover, we demonstrated that
iNOS was absent in all these models as well as in
human mesenchymal tumors. We showed that spe-
cific removal of eNOS-produced NO with the scav-
enger carboxy-PTIO (c-PTIO) impaired stem-related
signaling pathways essential for CSCs, which de-
creased in vitro tumorsphere and organoid formation
and in vivo tumor formation.
Results
eNOS is overexpressed in hyperproliferative regions and
tumors of Apcfl/fl, Apcfl/+, and Apcfl/+ PTENfl/+ intestinal
mouse tissue
To explore the role of NO in the generation and mainten-
ance of a CSC subpopulation, we used the CSC-specific Vil-
CreERT2 Apcfl/fl mouse model [25], where Apc-deficient cells
maintain a crypt progenitor-like phenotype associated with
the expansion of a stem Lgr5-positive cell population and
early colorectal lesions [26]. Whereas intestinal tissue sec-
tions from normal mice showed no expression of eNOS,
we found intense immunostaining for this NOS isoform in
epithelial cells from Apc-deficient crypts (Fig. 1a). However,
iNOS expression was absent in both wild-type (wt) and
Apc-deficient intestinal sections (Fig. 1a).
Deletion of both copies of Apc leads to a Wnt-
driven hyperproliferative phenotype. On the other
hand, the conditional deletion of a single copy of
Apc (VilCreERT2 Apcfl/+) leads to mice carrying 10–
20 discrete adenomas following spontaneous loss of
the wt Apc allele [27]. An analysis of the tumors
that arose in this mouse model showed that an in-
crease of eNOS expression was observed in tumor
regions. However, normal areas of the intestine that
still remained organized and where tumors were ab-
sent did not show any staining at the bottom of in-
testinal crypts (Fig. 1a). We also found this
upregulation of eNOS in intestinal adenomas from
Apcfl/+ mouse tissue by RT-qPCR compared with
normal intestinal tissue from the same animal
(Fig. 1b). The above results suggest that the increase
of NO production in mutant crypts through overex-
pression of eNOS isoenzyme occurs following loss of
Apc. Again, iNOS was not induced after the loss of
just one Apc allele (Fig. 1a). Similarly, invasive
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tumors from the more invasive VilCreERT2Apcfl/+
Ptenfl/+ mouse model showed an overexpression of
eNOS in tumors whereas normal crypts did not
show any expression of this isoenzyme (Fig. 1a). Ac-
cordingly, RT-qPCR analyses confirmed that eNOS
was almost threefold upregulated in the intestine of
VilCreERT2Apcfl/+ Ptenfl/+ mice compared with nor-
mal tissues (Fig. 1b). As found in the other two
mouse models, iNOS expression was absent in both
tumor and normal epithelium adjacent to the tumor
(Fig. 1a).
Therefore, the above results suggest that there
may be a relevant role for the upregulation of eNOS
expression in the early stages of CRC, where the
Lgr5-positive stem cell population is in expansion,
and also that the upregulation of this NOS isoform
is maintained in more advanced and invasive
genotypes.
eNOS is upregulated in the mesenchymal poor-prognosis
subtype and poorly differentiated human colorectal
tumors
We next evaluated the expression of NOS isoforms in dif-
ferent CRC subtypes. We classified 40 human colorectal
adenocarcinomas according to Sadanandam et al. [10] and
De Sousa et al. [6]. Thus, we obtained a supervised classifi-
cation of tumors into five molecularly distinct subtypes,
which are associated with different clinically relevant char-
acteristics: transit-amplifying, enterocyte, goblet-like, in-
flammatory, and stem-cell-like (Additional file 1: Figure S1
and Additional file 2: Figure S2).
The unsupervised classification (Fig. 2a) confirmed
the identification of this stem-like subgroup of tumors
that match the mesenchymal CMS4 group recently
defined by the International CRC Subtyping Consor-
tium [11]. We also analyzed the expression of cancer-
related human miRNAs in different classified tumors
Fig. 1 eNOS is upregulated in intestinal tumors from Apcfl/fl, Apcfl/+, and Apcfl/+ Ptenfl/+ mouse models. a eNOS and iNOS immunohistochemistry of
wild-type, Apcfl/fl, Apcfl/+, and Apcfl/+ PTENfl/fl mice intestinal tissues. eNOS expression was absent in the wild-type intestine whereas Apcfl/fl sections showed
intense immunostaining in the hyperproliferative crypts. In the Apcfl/+ and Apcfl/+ PTENfl/+ mice models, hyperproliferative areas resulted in upregulation of
eNOS (black arrows) whereas normal intestinal tissue did not show expression of this NOS isoform (red arrow). The bottom of normal crypts did not show
staining of eNOS (gray arrows). iNOS expression was absent in all three models. Scale bars: 100 μm and 200 μm. b RT-qPCR analysis of eNOS expression from
wild-type, Apcfl/+ and Apcfl/+ PTENfl/+ tissue. * P< 0.05 compared with the wild-type non-proliferative tissue. eNOS endothelial NO synthase, iNOS inducible
NO synthase, NOS NO synthase, RT-qPCR quantitative real-time reverse-transcriptase polymerase chain reaction, Wt wild type
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and we found a significant signature of 11 miRNAs,
which defines the mesenchymal subtype compared to
the other tumor subtypes (Additional file 3: Figure
S3a). The overexpression of miR-100, let-7e, and miR-
99a, which have been shown to be powerful regula-
tors of the epithelial-to-mesenchymal transition
(EMT) [28–30], was found in the mesenchymal tumor
subtype. However, miR-215 [31], miR-375 [32], miR-
141, and miR-200c [33], miR-200a [34], miR-429 [35],
miR-625 [36], and miR-18a [37] have already been
shown to be inversely correlated with the EMT, and
they were found downregulated in this subtype. Simi-
larly, we obtained a specific immune response in the
mesenchymal CRC subtype (Additional file 3: Figure
S3b), for which a significant increase of innate im-
mune cells was found (Additional file 4: Figure S4a)
as well as an upregulation of immune response genes
(Additional file 4: Figure S4b). All three signatures
generate a robust classification of the mesenchymal
tumors, which differentiate them from the other tu-
mors. Notably, the analysis of NOS isoforms showed
that, compared to the other non-mesenchymal CRC
subtypes, eNOS was highly expressed in the mesen-
chymal subtype whereas iNOS was nearly absent
(Fig. 2b). In agreement with RNA expression analyses,
protein expression (Fig. 2c) and immunohistochemical
studies (Fig. 3) confirmed the higher expression of
eNOS protein in mesenchymal tumors compared to
the other non-mesenchymal CRC subtypes.
The expression of iNOS was found in some human
colorectal tumors and it was restricted to just some ab-
errant crypts or even individual cells, unlike the general
high expression of eNOS in mesenchymal tumors
(Fig. 3). The induction of iNOS occurs in punctual re-
gions where proper inductive signals may lead to a
massive increase in its expression. This produces just
temporary high levels of NO, since this is energetically
unsustainable over time. Interestingly, immunohisto-
chemical analyses of unclassified high-grade poorly dif-
ferentiated tumors from CRC patients also showed the
upregulation of eNOS compared with non-proliferative
areas (Additional file 5: Figure S5). In line with these
Fig. 2 eNOS is significantly upregulated in human mesenchymal CRC tumors. a Unsupervised classification of the mesenchymal subgroup of CRC
tumors and non-mesenchymal subtypes. The heat map was generated using nSolver software from NanoString Technologies. b eNOS expression
as number of mRNA molecules detected. Te plots show normalized data of eNOS gene expression in all human CRC subtypes using the nCounter
system from NanoString Technologies. c eNOS Western blot analysis of total protein extracts of classified human CRC tumors. *P < 0.05, **P < 0.01,
****P < 0.0001 compared with non-mesenchymal tumors. CRC: colorectal cancer, eNOS: endothelial NO synthase, iNOS: inducible NO syn-
thase, CS-TA: colorectal subtype transit-amplifying
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results, a significantly decrease was found in 5-year sur-
vival in patients with CRC, colon adenocarcinoma, and
rectum adenocarcinoma when eNOS was upregulated.
However, a low expression of iNOS isoform decreased
the 5-year survival of these patients (Additional file 6:
Figure S6). Thus, as found for mesenchymal CRC tu-
mors, the overexpression of eNOS and low expression of
iNOS resulted in a poor prognosis in CRC. Overall, the
above results suggest that the eNOS isoform is the main
source of NO in mesenchymal poor-prognosis tumors.
eNOS is upregulated in intestinal epithelial organoids
derived from Apcfl/fl mice and NO scavenging decreases
their proliferation and stem-cell marker expression
Intestinal epithelial cells from wt or tamoxifen-
induced Apcfl/fl mice were cultured using the
organoid-forming assay and, whereas wt organoids
grew to form crypt-like structures, Apcfl/fl organoids
completely lost their intestinal structure (Fig. 4a).
Analysis of expression of NOS isoforms showed that
eNOS was highly expressed in Apc-deficient organoids
compared to their normal counterparts, whereas
iNOS was downregulated (Fig. 4b). This result sup-
ports again that the eNOS isoform could have an im-
portant role during the expansion of the Lgr5-positive
stem-cell subpopulation after Apc loss. Scavenging of
NO with c-PTIO, a compound that quickly reacts
with NO decreasing its concentration and bioavail-
ability for tumor cells, caused a significant decrease
of proliferation of Apcfl/fl organoids whereas wt orga-
noids grew normally (Fig. 4c,d). Moreover, NO deple-
tion also caused a marked decrease in the Lgr5+ cell
population both in wt and in Apcfl/fl organoids
(Fig. 4e). Furthermore, other stem-cell markers, in-
cluding Troy, Vav3, and Slc14a1, were downregulated
after NO scavenging (Fig. 4e). Thus, these results
Fig. 3 eNOS and iNOS immunohistochemistry in classified human CRC tumors. eNOS is highly expressed in human mesenchymal CRC tumors.
Mesenchymal tumors showed a high expression of eNOS whereas this isoenzyme was low or absent in non-mesenchymal tumors. iNOS expression
was found sporadically among the tumors and was restricted to particular areas or even individual cells where the induction may be triggered. Scale
bars: 100 μm. CRC: colorectal cancer, eNOS: endothelial NO synthase, iNOS: inducible NO synthase
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support again an important regulatory role of NO in
intestinal CSC biology.
NO depletion abolishes the capacity of CRC cells to form
tumorspheres and organoids in vitro and impairs CSC-
related pathways
To study the role of NO in the CSC subpopulation, we
performed tumorsphere experiments to characterize
the CSC subpopulation in vitro. This is a functional
assay of self-renewal capacity. We found that the pre-
treatment of HCT-116 and Caco-2 cells with c-PTIO
markedly inhibited their subsequent ability to form
tumorspheres (Fig. 5a). This effect was NO-specific
since the addition of NO donors, such as
DETANONOate or S-nitrosocysteine (CSNO), eradi-
cated the anti-CSC activity of c-PTIO in HCT-116 and
Caco-2 cells (Fig. 5a). Thus, these results suggest an
important regulatory role of NO in the self-renewal
capacity of colorectal CSCs. On the other hand, the
specific depletion of NO in HCT-116 and Caco-2 cells
led to a large decrease in the size and number of orga-
noids formed (Fig. 5b and Additional file 7: Figure S7).
This was a NO-specific effect since the use of NO do-
nors recovered the capacity of HCT-116 and Caco-2
cells to form organoids (Fig. 5b). From these results,
NO scavenging downregulated the levels of β-catenin,
Bmi1, Notch1, and Sox2 in HCT-116 and Caco-2 cells.
The use of NO donors showed again the capacity to
Fig. 4 eNOS is upregulated in organoids derived from Apcfl/fl mice intestine and NO trapping decreases their proliferation and downregulates the
expression of stem-cell markers. a Representative images from typical wild-type and Apcfl/fl organoids. Scale bars: 400 μm (left) and 200 μm (right).
b RT-qPCR analysis of iNOS and eNOS expression from wild-type and Apcfl/fl organoids. *P < 0.05 compared with the wild-type organoids. c and d
Proliferation assay of control or wild-type and Apcfl/fl organoids treated for 48 hours with c-PTIO (500 μM). Proliferation was determined by image
analysis with ImageJ software. *P < 0.05 compared with the control. Scale bars: 1000 μm. e RT-qPCR analysis of Lgr5, Troy, Vav3, and Slc14a1
expression from control or c-PTIO (500 μM) treated wild-type and Apcfl/fl organoids. eNOS endothelial NO synthase, iNOS inducible NO synthase,
RT-qPCR quantitative real-time reverse-transcriptase polymerase chain reaction, WT (wt, Wt) wild-type
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modulate key CSC signaling proteins depending on
the levels of this molecule (Fig. 5c). We also per-
formed a confocal immunofluorescence of β-catenin
in the Apc mutated Caco-2 organoids [38] and found a
downregulation of this protein after NO scavenging
(Fig. 5d). To rule out the contribution of iNOS in this
effect, we developed iNOS-knockdown HCT-116 cells
(Fig. 5e). Scavenging NO in this iNOS-deficient back-
ground showed the downregulation of all the men-
tioned proteins (Fig. 5f ), highlighting the relevance of
eNOS-produced NO.
The above results demonstrate a regulatory role for
NO in the CSC phenotype and emphasize the import-
ance of the production of this molecule by eNOS in
maintaining this phenotype. Moreover, NO scavenging is
shown to be an appealing alternative to the typically
used iNOS inhibitors in cancer, particularly in stem-cell-
like or mesenchymal tumors.
NO scavenging reduces the capacity of mesenchymal CRC
cancer cells to form tumors in xenograft mouse models
To explore the antitumor capacity of NO depletion fur-
ther, two different xenograft experiments were per-
formed using mesenchymal HCT-116 CRC cells [10].
Thus, control and c-PTIO-treated HCT-116 cells were
subcutaneously injected into immunocompromized
mice and then tumor progression was evaluated. As
shown in Fig. 6a, NO-depleted cells generated tumors
half the size of those generated from untreated control
cells. The decreased capacity of c-PTIO pre-treated
Fig. 5 eNOS-derived NO scavenging significantly impairs the CSC phenotype in human colon cancer cells. a Formation of tumorspheres from HCT-
116 and Caco-2 cells pre-treated for 24 hours with c-PTIO (100 μM) with or without DETANONOate or CSNO (100 μM). Representative images 1–2
weeks after seeding are shown. b Formation of organoids from cells pre-treated for 24 hours with c-PTIO (100 μM) with or without NO donors
(100 μM). Representative images 1–2 weeks after seeding are shown. c Immunoblot of β-catenin, Bmi1, Notch1, and Sox2 expression in HCT-116 and
Caco-2 tumor cells treated for 24 hours with c-PTIO (100 μM) with or without DETANONOate or CSNO (100 μM). d Organoid immunofluorescence of
β-catenin from control or Caco-2 organoids treated with c-PTIO (100 μM) for 24 hours. e RT-qPCR of iNOS-induced expression (IL-1β 3 ng/ml, IFN-γ
200 U/ml and TNF-α 75 ng/ml, for 6 hours) from control and iNOS-shRNA expressing HCT-116 cells. f Immunoblot of previously mentioned proteins in
iNOS-knockdown HCT-116 cancer cells treated with c-PTIO (100 μM). Stain-free technology was used as loading control in immunoblot experiments. *
P < 0.05 compared with the control. Scale bars: 100 μm. CSC cancer stem cell, CSNO S-nitrosocysteine, eNOS endothelial NO synthase, iNOS inducible
NO synthase, RT-qPCR quantitative real-time reverse-transcriptase polymerase chain reaction
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cancer cells to form larger tumors suggest a long-term
effect of scavenging NO and an important role of this
molecule in the regulation of CSCs. On the other hand,
to elucidate the antitumor effectiveness of c-PTIO in
vivo, HCT-116 cells were subcutaneously injected into
immunocompromized mice and animals were then
treated with 320 mg/kg of c-PTIO once a week. The
treatment had no toxic effects and did not cause weight
loss during the experiment (Fig. 6b). In vivo c-PTIO
treatment attenuated tumor growth (Fig. 6c) and final
tumor volume was significantly decreased compared
with that of untreated control mice (Fig. 6d,e). Interest-
ingly, tumor xenografts did not show any expression of
iNOS whereas eNOS was found highly expressed in
both epithelial and endothelial cells (Fig. 6f ). Thus, the
effect of c-PTIO was the result of eNOS-produced NO
scavenging, the main source of this molecule in a mes-
enchymal tumor. Moreover, the expression of β-catenin
and the relevant target for cancer therapeutics, Bmi1
[39], were found decreased in tumors after c-PTIO
treatment (Fig. 6). Again, these results further support
a key role of eNOS-derived NO in CSC maintenance
and show NO scavenging as an attractive alternative for
targeting this tumor subpopulation.
Discussion
Although there is emerging evidence indicating that CSCs
are responsible for cancer aggressiveness, chemoresis-
tance, and relapse, which results in high mortality rates
[40], there is a little knowledge about their regulation. Dif-
ferent biological mediators in tumor microenvironments
may cause reversible changes in a CSC population [41].
The iNOS isoform has been shown to be the predominant
enzyme that promotes tumor progression through NO
production [42] and has prompted the search for new
therapies based on inhibitors against the iNOS isoform
[43]. Nevertheless, there is a huge controversy about the
role of iNOS in colon cancer [16–20], and this approach
offers a limited therapeutic benefit in contexts where con-
stitutive isoforms are the main or even the only source of
Fig. 6 NO trapping with c-PTIO reduces the capacity of mesenchymal HCT-116 cells to form tumors in xenografted mice and decreases expression in
vivo of β-catenin and Bmi1. a Control or HCT-116 cells pre-treated with c-PTIO (100 μM) for 24 hours were subcutaneously injected into the flanks of
immunocompromized mice. Final tumor volumes were analyzed after 37 days of inoculation. Mice xenografted with HCT-116 cells were treated with
vehicle or c-PTIO (320 mg/kg) once a week. b Mice weights were monitored over time. c Tumor size was measured during the course of treatment.
d and e Final tumor volume was analyzed after harvesting. f Representative images from immunohistochemistry of eNOS and iNOS from HCT-116-
derived tumors and β-catenin and Bmi1 from vehicle or c-PTIO treated mice tumors. *P < 0.05, **P < 0.01, ***P < 0.001 compared with control. eNOS
endothelial NO synthase, iNOS inducible NO synthase
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NO [44]. Moreover, there are non-enzymatic sources of
NO, which are not blocked by NOS inhibitors [45]. Fur-
thermore, NO scavenging shows a second-order reaction
kinetic, decreasing NO preferentially in regions of aber-
rant overproduction and having a light impact on essential
basal NO levels [46]. Thus, NO scavengers emerge as an
alternative approach to targeting this molecule before it
can exert its effects, trapping NO from all sources.
In 1997, Takahashi et al. showed there was increased ex-
pression of eNOS in endothelial cells of azoxymethane-
induced rat colon tumors [47]. Although the effects of
NO from the eNOS isoenzyme on tumorigenesis have
been mainly related to its expression in endothelial cells
[48], tumor-expressed eNOS and its role in initiation and
maintenance of the tumorigenic process have been previ-
ously shown in other tumors [24]. Actually, an upregula-
tion of eNOS expression was found in undifferentiated
regions compared to differentiated tumor areas in a mur-
ine mammary tumor model, and strongly eNOS-positive
tumor cells have been found in lung metastatic sites [44].
Here, to elucidate the role of NO in CSC biology, we
used the early tumorigenesis VilCreERT2 Apcfl/fl mouse
model, where the deletion of both copies of this gene re-
sults in a crypt progenitor-like phenotype characterized
by augmented proliferation and CSC subset expansion
[49]. Epithelial cells from intestinal Apcfl/fl crypts showed
intense immunostaining of eNOS, whereas crypts from
wt mice did not show any expression of this isoenzyme.
In fact, the conditional VilCreERT2 Apcfl/+ mouse model
showed that the haploinsufficiency of the Apc gene is
enough to upregulate the expression of eNOS and in-
crease the production of NO in tumors. These results
support the relevance of eNOS isoform in this context
of Lgr5-positive stem cell expansion. The production of
NO in the colon has been linked with a higher risk of
colon cancer [50] and our results suggest that the eNOS
isoenzyme seems to be an important source of these
molecules in early mutational events of the disease.
Similarly, invasive tumors from the more invasive Vil-
CreERT2Apcfl/+ Ptenfl/+ mouse model showed that eNOS
was upregulated in tumors whereas normal crypts did
not show any expression. Interestingly, iNOS expression
was absent in all three independent mouse models, sup-
porting the hypothesis that eNOS is the most relevant
NOS during the first stages of the disease.
We also classified 40 human colorectal tumors into five
molecular subtypes according to Sadanandam et al. [10]
and De Sousa et al. [6]. The stem-like subtype matches
the mesenchymal CMS group of the most robust classifi-
cation system currently available for CRC and has the
worst relapse-free and overall survival [11]. This mesen-
chymal phenotype has been shown to be regulated by dif-
ferent pleiotropic-acting molecules, including miRNAs
[51]. Here, we obtained a significant signature of 11
miRNAs, which differentiates the mesenchymal subtype
from the other tumors. Similarly, we obtained a specific
immune response in the classified human mesenchymal
tumors. In particular, a significant increase of dendritic
cells, CD45 cells, macrophages, and mast cells was found
in mesenchymal tumors. This is consistent with the fact
that the stromata of these tumors are infiltrated with
endothelial cells, cancer-associated fibroblasts, and also
innate immune cells [11, 52]. Moreover, these tumors
showed an upregulation of immune response genes such
as complement signaling genes, whose overexpression has
been shown in mesenchymal tumors [11]. These three sig-
natures generate a robust classification of the mesenchy-
mal tumors, which differentiates them from the other
tumors. Notably, gene expression analysis of NOS iso-
forms revealed that eNOS was significantly upregulated in
the mesenchymal subtype whereas iNOS was absent. This
result suggests that eNOS is the most relevant enzymatic
source of NO in this poor-prognosis tumor subtype and
may represent an active stem-cell regulatory point in can-
cer as well as a possible target for therapy against aggres-
sive human tumors.
In vitro tumor organoid models could be used to inter-
rogate the sensitivity toward different drugs and to predict
patient response [53]. Here, we found that eNOS was sig-
nificantly upregulated in Apcfl/fl organoids compared to
their normal counterparts whereas iNOS was downregu-
lated. Moreover, we showed that scavenging NO with the
highly specific NO scavenger c-PTIO [54] significantly de-
creased the proliferation of Apc-deleted organoids, mark-
edly decreasing the Lgr5 population and downregulating
the expression of other stem-cell markers including Troy
[55], Vav3 [56], and Slc14a1 [57]. These results support
again the implication of NO in maintaining the CSC
phenotype. Moreover, the withdrawal of NO with c-PTIO
impaired the CSC phenotype of CRC cells, decreasing
their self-renewal capacity and the expression of key pro-
teins considered as putative targets in CSC signaling path-
ways, such as Notch, β-catenin, and Bmi1 [3]. The effect
was molecule-specific since the use of NO donors allowed
tumor cells to recover their initial phenotype and abro-
gated the anti-CSC effect of c-PTIO. Furthermore, scaven-
ging NO with c-PTIO in iNOS-knockdown HCT-116
cells also resulted in an impairment of the CSC pheno-
type, highlighting the relevance of eNOS-produced NO.
These results suggest that targeting CSC self-renewal
through NO scavenging could be a valuable approach in
cancer therapy.
According to the CSC model, only this subset of tumor
cells has the capacity to generate tumors in xenotransplant-
ation experiments with immunocompromized mice due to
its self-renewal properties and wide proliferative potential
[58]. Herein, the abrogation of NO for 24 hours generated
tumors with 50% less volume in a xenograft model with
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mesenchymal HCT-116 CRC cells. This result supports the
idea that NO trapping causes long-term changes in the
CSC phenotype of tumor cells, decreasing their enormous
proliferative capacity. Furthermore, we found an impaired
tumor growth capacity in c-PTIO-treated mice, which
formed tumors significantly smaller than those of untreated
mice. These tumors did not show iNOS expression,
whereas intense immunostaining of eNOS was found.
Moreover, tumors formed in c-PTIO-treated animals
showed a downregulation of β-catenin and Bmi1 expres-
sion, which is a key protein required for CSC function in
colorectal tumors and represents an effective target for con-
trolling tumor growth [59].
Conclusion
In summary, our data show that eNOS upregulation is as
an early event in CRC together with Apc loss and this
overexpression is maintained in other more advanced
tumor genotypes. This isoenzyme is upregulated in differ-
ent scenarios where the CSC phenotype is enhanced, in-
cluding different mice conditional CRC models, human
mesenchymal CMS tumors, and poorly differentiated ag-
gressive adenocarcinomas. Moreover, the NO scavenger c-
PTIO has been shown to impair the stem-related signaling
pathways essential for CSCs in vitro and to have an anti-
proliferative effect in vivo, decreasing β-catenin and Bmi1
expression in a xenograft mouse model. Since targeting
the CSC population is increasingly becoming a priority in
cancer research, our results indicate that eNOS is an un-
expected potential new target in human poor-prognosis
mesenchymal colorectal tumors.
Methods
Patients and inclusion criteria
Forty patients over 18 years of age with resectable CRC
and submitted to surgery in Reina Sofía Hospital
(Córdoba, Spain) were included in the study, which was
approved by the Reina Sofía Hospital ethical committee.
Signed informed consent was obtained from each patient.
Classification into colon cancer subtypes
We used the nCounter Element system from NanoString
to analyze the RNA expression of a set of genes and clas-
sify CRC samples according to Sadanandam et al. [10]
(five subtypes) and De Sousa et al. [6] (three subtypes),
both classifiers strongly relating to each other. Data ana-
lysis was performed using nSolver software (NanoString
Technologies, Seattle, WA, USA) to manage the raw data
generated for the expression of each gene. Then, the raw
data expression readouts were normalized and an overall
average (mean) was established for each gene. The positive
expression of one particular gene indicates that the num-
ber of RNA molecules is above the average, whereas nega-
tive expression indicates that it is below the mean of the
number of RNA molecules. An miRNA signature from
different tumor subtypes was obtained using the nCounter
human v3 miRNA expression assay from NanoString.
Tumor immune response in the different tumor subtypes
was obtained using the nCounter PanCancer immune-
profiling panel from NanoString.
Immunohistochemistry
First, 4-μm-thick sections were mounted on poly-L-lysine
coated slides, deparaffinized in xylene, and rehydrated using
graded alcohols. Antigen retrieval was accomplished with a
10 mM citrate buffer (pH 6.0) at 95–98 °C for 20 min. En-
dogenous peroxidase was neutralized using EnVision FLEX
peroxidase-blocking reagent (Dako, Denmark) for 10 min.
Tween-phosphate-buffered saline (PBS) was used as the
washing solution. Tissue sections were blocked with 3% bo-
vine serum albumin and the mouse-on-mouse staining
protocol (Abcam) was used for mouse samples with eNOS
mouse-produced antibody. Anti-eNOS (6H2) (1:200, Cell
Signaling, Danvers, MA, USA, ref 02/2016, lot 2, RRID
AB_10850618), anti-iNOS (1:100, Invitrogen, lot RJ2276825,
RRID AB_2537941), anti-Bmi1 (1:400, Abcam, lot
GR301384-1, RRID AB_2065390), and β-catenin (BD, East
Rutherford, NJ, USA, 1:100, lot 5121508, RRID AB_397554)
were used as primary antibodies. EnVision FLEX+mouse
(linker) (Dako) was use for eNOS staining in mouse sam-
ples. EnVision FLEX/HRP (Dako K8000) was used as the
secondary antibody for 30 min at room temperature,
followed by 3,3'-diaminobenzidine (DAB) staining (Dako li-
quid DAB+ substrate chromogen system, Dako). Sections
were then counterstained with hematoxylin, dehydrated,
and mounted.
Quantitative real-time reverse-transcriptase polymerase
chain reaction
Total RNA extraction was performed using RNeasy Mini
Kit (Quiagen, Hilden, Germany) following the manufac-
turer’s recommendations. iScript gDNA clear cDNA syn-
thesis kit (Bio-Rad) was used to obtain cDNA and real-
time PCR was performed using Sensifast SYBR NO-
ROX mix (Bioline, London, UK). Expression levels of
eNOS, iNOS, Lgr5, Troy, Vav3, and Slc14a1 were mea-
sured by quantitative real-time PCR (qPCR) using Light-
Cycler 480 Instrument II (Roche, Basel, Switzerland).
Primer sequences are described in Additional file 8:
Table S1. Results were normalized to glyceraldehyde 3-
phosphate dehydrogenase (GADPH) and relative expres-
sion was determined by the 2-ΔΔCt method.
Chemicals
c-PTIO was purchased from Sigma-Aldrich (St Louis,
MO, USA) and DETANONOate from Cayman Chemical
(Ann Arbor, MI, USA). S-nitrosocysteine (CSNO) was
synthesized as previously described [60] by incubation of
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L-cysteine with acidified sodium nitrite and quantifica-
tion by absorbance at 334 nm using a molar absorption
coefficient of 0.74/mM/cm. IL-1β, IFN-γ, and TNF-α
were purchased from R&D Systems.
Cell cultures
HCT-116 cells (DSMZ, Braunschweig, Germany) were
grown in McCoy’s 5A medium (Biowest) containing 10%
fetal bovine serum (FBS) (PAA Laboratories, Pasching,
Austria). Caco-2 cells (ECACC, Salisbury, UK) were
grown in MEM medium (Biowest, Nuaillé, France)
containing 15% FBS (PAA Laboratories) and MEM non-
essential amino acids (Biowest). Culture media were sup-
plemented with 2 mM glutamine (Biowest) and Zell
Shield antibiotics (Minerva Biolabs, Berlin, Germany).
Cells were maintained in a humidified atmosphere at
37 °C and 5 °C CO2.
Western blot analysis
Cells were treated with c-PTIO, c-PTIO and DETA-
NONOate, or CSNO for 24 hours and protein lysate ex-
traction and immunoblotting were performed as described
elsewhere [61]. Primary antibodies recognizing Notch1
(Abcam, Cambridge, UK, 1:2000, lot GR215257-19, RRID
AB_881725), Bmi1 (Abcam, 1:5000), β-catenin (BD,
1:2000) and Sox2 (R&D Systems, Minneapolis, MN, USA
1:1000, lot KOY0212101, RRID AB_355110) were used.
Stain-free technology (Bio-Rad, Hércules, CA, USA) was
used as loading protein control and densitometric analysis
was performed with Image Lab software (Bio-Rad).
Colonosphere formation assay
Cells were treated while growing in adherence and then
trypsinized and seeded at clonal density (1 cell/μL) in
ultra-low attachment surface 96-well plates (Costar,
Corning, NY, USA) with serum free Dulbecco’s MEM
Nutrient Mixture F + 12 HAM (Sigma-Aldrich) supple-
mented with 1× B27 (Invitrogen, Carlsbad, CA, USA),
10 ng/ml bFGF (Prepro Tech, London, UK), 20 ng/ml
EGF (Santa Cruz Biotechnology, Heidelberg, Germany)
and 1% (v/v) methylcellulose (R&D Systems) to prevent
cell aggregation. Every 2–3 days, freshly supplements
were added. The number and size of colonospheres were
analyzed by optical microscopy 1–2 weeks after seeding.
Organoid formation assay
Cells were treated while growing in adherence and then
trypsinized and embedded in Matrigel (growth factor re-
duced, phenol red free; BD) on ice and seeded in 24-well
plates (10–25 single cells/μL of Matrigel per well). The
Matrigel was polymerized for 10–15 min at 37 °C and
then 500 μL/well basal culture medium (advanced
DMEM/F12) supplemented with Zell Shield antibiotics
(Minerva Biolabs), 1× B27 and 1× N2 (Thermo
Scientific, Waltham, MA, USA) was added. The number
and size of organoids were analyzed by optical micros-
copy 1–2 weeks after seeding.
For wt or VilCreERT2Apcfl/fl mouse organoids, crypts,
fragments of epithelium, or single cells were seeded in 24-
well plates (50 and 10 fragments per 10 μL of Matrigel per
well, respectively). After 24 hours, organoids were treated
with c-PTIO for 48 hours and proliferation was deter-
mined by analyzing the images with ImageJ software.
Confocal immunofluorescence: in situ staining of
organoids within Matrigel
Cells were plated in 60 μL of Matrigel in μ-slide eight-well
ibiTreat chamber slides (Ibidi, Martinsried, Germany) and
overlaid with advanced DMEM/F12 supplemented with
Zell Shield antibiotics, 1× B27 and 1× N2 supplement.
Cell-derived organoids were observed for 16 days and
then they were fixed in situ for 5 min each with −20 °C
100% methanol and 2% formaldehyde in PBS. The cham-
bers were washed twice for 5 min with PBS and once for
5 min with PBS-Tween. The slides were blocked with 3%
bovine serum albumin for 30 min and incubated with β-
catenin antibody (BD, 1:50) at 4 °C overnight and washed
three times for 5 min with PBS-Tween. Organoids were
then incubated with Alexa Fluor 488 secondary antibody
(Thermo Fisher, 1:200) at 4 °C overnight and were washed
three times for 5 min with PBS-Tween. Nuclei were
stained with DAPI and serial images were taken using a
Zeiss LSM 710 confocal microscope.
Lentiviral particles transduction and iNOS-silenced clone
selection
HCT-116 cells were seeded (12,000 cells/well) in 96-well
plates to be transduced at 50–80% confluency. To enhance
the transduction, 8 μg/ml hexadimethrine bromide (Sigma-
Aldrich) was added to the cells. Then, viral particles con-
taining iNOS shRNA or non-target control shRNA were
added at 5× multiplicity of infection and the cell–viral par-
ticle mixture was incubated at 37 °C overnight. After incu-
bation, the viral-particle-containing medium was removed
and replaced with fresh complete culture medium. Cells
were expanded to obtain a sufficient amount for selection
of transduced cells. Then, cells were harvested in filtered
(0.2 μm) basic sorting buffered (1× phosphate buffer,
2 mM EDTA, 25 mM HEPES pH 7.0, 2% FBS, and Zell
Shield antibiotics) and green fluorescent protein-positive
cells were sorted by flow cytometry (FACSAria III, BD)
with a 100-μm nozzle in a cloning 96-well plate. Clones
were grown in 50% FBS complete medium and iNOS
downregulation was confirmed by RT-qPCR.
Mouse xenograft model
The experiment with mice was approved by the Instituto
Maimónides de Investigación Biomédica de Córdoba
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(IMIBIC) Ethical Committee and followed all the ethical
protocols established. To establish a subcutaneous colorec-
tal xenograft model, control cells or cells treated with c-
PTIO for 24 hours (2.5 × 106 HCT-116 in 100 μL Matrigel)
were implanted subcutaneously into the flanks of 5-week-
old immunocompromized male NOD/SCID mice
(NOD.CB17/AlhnRj-Prkdcscid, Janvier Labs). The experi-
ment was terminated 37 days post injection and tumor vol-
ume was analyzed. To evaluate the in vivo effectiveness of
c-PTIO, both hind flanks of 6-week-old male NOD/SCID
mice (NOD.CB17/AlhnRj-Prkdcscid, Janvier Labs) were
injected subcutaneously with 4 × 106 HCT-116 cells in
100 μL Matrigel. Eight-week-old mice were treated with one
intraperitoneal injection per week of c-PTIO (320 mg/kg)
or vehicle (PBS). Tumor growth was measured weekly using
a digital caliper. The apparent tumor volume was calculated
as lw2/2 and final tumor volume as (π/6) × lw×h (l:lenght;
w:width; h:height).
Statistical analysis
Student’s test was used to test for statistical significance.
Error bars represent mean ± standard deviation.
Additional files
Additional file 1: Figure S1. Qualitative supervised classification of
human CRC tumors into different CRC subtypes. Data analysis was
performed using nSolver software from NanoString Technologies. Raw
expression data were normalized and an overall average was established
for each classifier gene, as described by Sadanandam et al. [10] and De
Sousa et al. [6]. Positive expression indicates a value of expression above
the average and it is shown as a green square, whereas negative
expression is a value below the overall mean and it is shown as a red
square. (TIF 64176 kb)
Additional file 2: Figure S2. Relative expression of classifier genes in all
tumor samples. List of classifiers genes used and their relative expression
in all tumor samples: mesenchymal, transit-amplifying, goblet-like, entero-
cyte, and inflammatory. Data analysis was performed as described in
“Methods.” (TIF 51415 kb)
Additional file 3: Figure S3. The human mesenchymal CRC subtype
has a specific miRNA and tumor immune response signature. Heat maps
were generated using nSolver software from NanoString Technologies. a
miRNA signature of mesenchymal tumors compared with other non-
mesenchymal subtypes. b Tumor immune response signature of mesen-
chymal tumors compared with non-mesenchymal tumors. (TIF 59213 kb)
Additional file 4: Figure S4. NanoString immune-profiling analysis of
mesenchymal and non-mesenchymal tumors. Mesenchymal CRC sub-
type has a significant increase of innate immune cells and immune
response genes related with adhesion, cell cycle, complement,
leukocyte, microglial, senescence, Toll-like receptor, and transporter
functions. RNA isolated from human CRC tumors was analyzed using
the NanoString nCounter PanCancer immune profiling panel. a Profil-
ing of tumor-associated immune-cell-type markers in mesenchymal
and non-mesenchymal tumors. b Expression profiling of immune-
related functions in each group of tumors. Expression values are
expressed as log2. (TIF 61809 kb)
Additional file 5: Figure S5. Immunohistochemistry of eNOS in non-
classified CRC tumors. eNOS is highly expressed in advanced poorly dif-
ferentiated human tumors. Hyperproliferative areas showed intense stain-
ing of this isoenzyme (black arrow), whereas areas that still maintain a
normal structure did not show any expression (red arrow). Scale bars:
100 μm. (TIF 16867 kb)
Additional file 6: Figure S6. Kaplan–Meier plots from an analysis of the
correlation between eNOS (a) or iNOS (b) mRNA expression level and
patient survival using the best separation. eNOS upregulation and low
iNOS expression significantly decrease the 5-year survival in colorectal
cancer, colon adenocarcinoma and rectum adenocarcinoma patients. Pa-
tients were divided into low or high groups based on the level of expres-
sion of the NOS isoform. Data were taken from The Human Protein Atlas
database. (TIF 76270 kb)
Additional file 7: Figure S7. Timeline of organoid formation in control
or c-PTIO (100 μM) pre-treated HCT-116 and Caco-2 tumor cells. NO scaven-
ging with c-PTIO impairs the capacity of CRC cells to form organoids and al-
ters the morphology of Caco-2 organoids.Scale: 100 μm. (TIF 50492 kb)
Additional file 8: Table S1. Mouse primer sequences used in this
study. (TIF 45302 kb)
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